A LS is a neurodegenerative disease characterized by the loss of motor neurons 1 . Patients with ALS experience progressive paralysis, usually succumbing to disease 1-5 years after diagnosis 2 . Aside from two Federal Drug Administration approved drugs, which only modestly slow disease, treatment for ALS is limited to supportive care 3 . ALS is recognized to be on the same pathological spectrum as frontotemporal dementia (FTD), the most common cause of pre-senile dementia 4 . Although the causes of most ALS and FTD cases remains unknown, pathological findings and family-based linkage studies have demonstrated overlap in molecular pathways involved in both diseases 1 . In a landmark finding, TDP-43 was discovered to be a major constituent of inclusions in many sporadic cases of ALS and FTD 5 . TDP-43 is a predominantly nuclear DNA/RNA-binding protein with functional roles in transcriptional regulation, splicing, pre-microRNA processing, stress granule formation and messenger RNA transport and stability 6, 7 . Subsequently, autosomal-dominant mutations in its gene TARDBP were identified in both ALS and FTD families, linking genetics and pathology with neurodegeneration 7, 8 . Thus, elucidating the role that perturbations to TDP-43 play in disease is essential to understanding both sporadic and familial ALS.
A LS is a neurodegenerative disease characterized by the loss of motor neurons 1 . Patients with ALS experience progressive paralysis, usually succumbing to disease 1-5 years after diagnosis 2 . Aside from two Federal Drug Administration approved drugs, which only modestly slow disease, treatment for ALS is limited to supportive care 3 . ALS is recognized to be on the same pathological spectrum as frontotemporal dementia (FTD), the most common cause of pre-senile dementia 4 . Although the causes of most ALS and FTD cases remains unknown, pathological findings and family-based linkage studies have demonstrated overlap in molecular pathways involved in both diseases 1 . In a landmark finding, TDP-43 was discovered to be a major constituent of inclusions in many sporadic cases of ALS and FTD 5 . TDP-43 is a predominantly nuclear DNA/RNA-binding protein with functional roles in transcriptional regulation, splicing, pre-microRNA processing, stress granule formation and messenger RNA transport and stability 6, 7 . Subsequently, autosomal-dominant mutations in its gene TARDBP were identified in both ALS and FTD families, linking genetics and pathology with neurodegeneration 7, 8 . Thus, elucidating the role that perturbations to TDP-43 play in disease is essential to understanding both sporadic and familial ALS.
Whether neurodegeneration associated with TDP-43 pathology is the result of loss-of-function mechanisms, toxic gain-of-function mechanisms or both remains unclear 7 . Early studies showed that overexpression of wildtype and mutant TDP-43 led to its aggregation and nuclear loss 7 . While these studies along with the autosomal-dominant inheritance pattern of TARDBP mutations support a gain-of-function view, the loss of nuclear TDP-43 and its aggregation suggests its normal functions might also become impaired. Subsequent findings revealed that TDP-43 depletion in the developing embryo or motor neurons have profound consequences 9 . Given the myriad roles TDP-43 plays, a key question is: what RNA substrates are perturbed on alterations of TDP-43 localization or by TDP-43 mutation and how do they contribute to neurodegeneration? Initial efforts to answer this question used cross-linking and immunoprecipitation with RNA-sequencing of whole brain homogenates 10, 11 . These studies led to an understanding that many transcripts are regulated by TDP-43 with a preference towards RNAs containing UG repeats and long introns; however, the prominence of glial RNAs in the samples limited insights into the neuronal targets of TDP-43. Consequently, few clear connections between the TDP-43 target RNAs and neurodegenerative mechanisms have been forged.
To identify substrates potentially contributing to neurodegeneration, we sought to identify RNAs regulated by TDP-43 in human
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NATuRe NeuRoScieNce motor neurons. Because the vulnerable neurons in living ALS patients are fundamentally inaccessible for isolation, we and others have developed approaches for directing the differentiation of human pluripotent stem cells into human motor neurons (hMNs) [12] [13] [14] .
Here, we performed RNA-Sequencing (RNA-Seq) after TDP-43 knockdown in hMNs and identified TDP-43-regulated transcripts in this cellular context. In total, we found 885 transcripts for which TDP-43 was needed to maintain normal RNA levels. Although any number of these targets may play subtle roles in neurodegeneration, we noted that one of the most abundant transcripts in hMNs encoding STMN2, also known as SCG10 a regulator of microtubule stability, was particularly sensitive to a decline in TDP-43. Additionally, we determined that STMN2 levels were also decreased following pharmacological induction of TDP-43 relocalization from the nucleus and in induced pluripotent stem cell-(iPSC-) derived hMNs generated from patients with TDP-43 mutations 15 . We further show that STMN2 encodes a protein necessary for normal hMN outgrowth and repair. Importantly, we established that post-translational stabilization of STMN2 through inhibition of c-Jun N-terminal kinases (JNK) can rescue deficits in motor neurite outgrowth and axon regeneration induced by TDP-43 knockdown. Finally, STMN2 depletion resulting from loss of TDP-43 activity is probably relevant to people with ALS, as we found that STMN2 expression is decreased in the spinal cord of ALS patients postmortem.
Results

Motor neuron RNAs regulated by TDP-43.
To produce hMNs for studying RNAs regulated by TDP-43, we differentiated the human embryonic stem cell (hESC) line HUES3 Hb9::GFP 13 into GFP + hMNs under adherent culture conditions. On day 14 of differentiation, we routinely obtained cultures comprised of approximately 18-20% GFP + cells. Subsequent analysis of these GFP The reduced levels of nuclear TDP-43 observed in ALS has been hypothesized to contribute to downstream neurodegenerative events through alterations in the metabolism of the RNAs it binds 7 . We, therefore, sought to identify the RNAs regulated by TDP-43 in purified hMNs through a combination of knockdown and RNASeq approaches. Using a fluorescently conjugated siRNA (siRED), we validated transfection conditions to achieve high-levels of siRNA delivery (~94%). We then used a quantitative reverse transcription-polymerase chain reaction (qRT-PCR) to validate that TDP-43 mRNA levels had been depleted in hMNs treated with siTDP43s, but not in those exposed to a scrambled siRNAs. We further confirmed TDP-43 depletion at the protein level by immunoblot, with siTDP43-treated hMNs showing a 54-65% reduction in TDP-43 levels ( Supplementary Fig. 2a-e) .
To measure global alterations in transcript abundance following partial loss of TDP-43, we prepared RNA-Seq libraries from siRNA-treated hMNs (Fig. 1a) . After next-generation sequencing, we obtained expression data for each gene annotated as transcripts per million (TPM). After initial clustering ( Supplementary Fig. 3a ), principle components analyses focused on the 500 most differentially abundant transcripts segregated the samples on the basis of siTDP-43 treatment (PC1), indicating that reduction of TDP-43 levels accounted for the greatest differences in transcript abundance, followed by the particular batch of hMNs produced (PC2) (Fig. 1b) . Inspection of TPM values for TDP-43 expression confirmed that its abundance was significantly reduced in siTDP43-treated hMNs ( Supplementary Fig. 3b) .
We next performed differential gene expression analysis, which at a false discovery rate of 5%, identified 885 significantly differentially expressed transcripts after TDP-43 knockdown (Fig. 1c,d ).
Expression was significantly higher for 392 transcripts ('increased abundance') and significantly lower for 493 transcripts ('decreased abundance') in TDP-43-depleted hMNs (Fig. 1c,d ). In addition to altering transcript levels of hundreds of genes 10 , reduced levels of TDP-43 can also influence RNA splicing 7, 10 . We therefore analyzed differential exon usage, which at a false discovery rate of 10%, identified 815 statistically differentially expressed exons in hMNs after TDP-43 knockdown (Fig. 1e) . In these cells, values were significantly higher for 493 exons ('increased abundance') and lower for 322 exons ('decreased abundance') ( Fig. 1e) . Reassuringly, we detected POLDIP3 as a top candidate for altered splicing (Fig. 1e) , which has previously been associated with deficits in TDP-43 function 16, 17 . Additionally, we detected splicing changes in 50 of the 885 transcripts differentially expressed following TDP-43 knockdown including the abundant transcripts STMN2 and PFKP (Fig. 1c-e) .
Of the 885 altered transcripts, we selected a subset for further validation. We considered transcripts with enriched neuronal expression (STMN2 18, 19 , ELAVL3 20 ), those associated with neurodevelopment/ neurological disorders (RCAN1 21 , NAT8L
22
) and those with reasonable expression levels or large fold changes (SELPLG, NAT8L). To this end, we obtained RNA from independent biological motor neuron replicates after TDP-43 knockdown and determined by qRT-PCR the relative abundance of nine candidate transcripts. Notably, we confirmed differential expression for seven out of nine RNAs after treatment with siTDP43, validating the quality and reproducibility of our RNA-Seq analyses (Fig. 1f,g ).
STMN2 levels downregulated in hMNs expressing mutant TDP-43.
We proceeded to ask if any RNAs with altered abundances after TDP-43 depletion were perturbed by expression of mutant TDP-43. Directed differentiation approaches tend to yield heterogeneous cultures making quantitative, comparative analyses between individual iPSC lines challenging 23 . Residual, mitotic progenitor cells are especially troublesome as they can overtake cultures. To overcome this, we performed an unbiased fluorescent activated cell sorting-(FACS-) based immunoprofiling analysis on HUES3 Hb9::GFP + hMNs to identify antigenic signatures enriched on both postmitotic neurons and cycling progenitors ( Supplementary  Fig. 4a ). These studies revealed that by isolating NCAM + /EpCAM − cells, we could obtain neuronal cultures with reproducible properties ( Supplementary Fig. 4b-i) .
Using this method, we isolated neurons from five control iPSC lines and four iPSC lines with distinct TDP-43 mutations ( Fig. 2a and Supplementary Fig. 5a ). As anticipated, each cell line exhibited its own differentiation propensity into hMNs ( Supplementary  Fig. 4f-g ), but after sorting we could readily obtain homogenous neuronal cultures from each line (Fig. 2b) . We used these hMNs to explore how mutations in TARDBP influence TDP-43 localization, solubility and ability to regulate select RNA targets. The majority of mutations in TDP-43 are dominant missense mutations in the C-terminal glycine-rich domain, but how mutations trigger disease or if all mutations are equivalent remains unclear 7 . Previous studies have reported that iPSC-derived neuronal cultures expressing mutant TDP-43 recapitulate some aspects of TDP-43 pathology including its accumulation in both soluble and insoluble cell protein extracts, as well as some cytoplasmic mislocalization [24] [25] [26] . We first tested whether expression of mutant TDP-43 was sufficient to induce cytoplasmic mislocalization using immunofluorescence ( Fig. 2b and Supplementary Fig. 5b ). However, we did not find this to be the case. In both control and mutant neurons, we observed primarily nuclear TDP-43 staining using two different metrics. Pearson's coefficient analysis revealed a strong correlation between TDP-43 immunostaining and the DNA counterstain for both groups (Fig. 2c) . We also calculated the nuclear to cytoplasmic ratio of TDP-43 staining with no significant difference observed between Articles NATuRe NeuRoScieNce groups ( Supplementary Fig. 5c ). Moreover, we did not detect differences in the abundance of TDP-43 protein by immunoblot analysis in either the soluble or insoluble fractions ( Supplementary  Fig. 5d-e) . These results are consistent with some TDP-43 iPSC disease modeling studies 26 , yet inconsistent with others 24 and suggested to us that additional perturbations could be required to induce TDP-43 mislocalization 27 .
Although we did not detect gross changes to TDP-43, we hypothesized that TARDBP mutations might impact the metabolism of a subset of TDP-43 target RNAs. Thus, we collected RNA from hMNs and performed qRT-PCR to investigate levels of the transcripts most reproducibly impacted by TDP-43 depletion (ALOX5AP, STMN2, ELAVL3, PFKP and RCAN1). We tested for significant differences between control (n = 9) and TDP43 knockdown (n = 6) samples, which are highlighted, using the Wald test and a cutoff of 0.05 for BenjaminiHochberg adjusted P values with no log 2 fold-change ratio cutoff. d, Differential transcript abundance scatter plot comparing TPM values for all transcripts expressed in hMNs treated with control siRNAs vs. the fold change in expression for those transcripts in cells treated with siTDP43. e, Differential exon usage scatter plot comparing TPM values for individual exons expressed in hMNs treated with siTDP43 siRNAs vs. the fold change in expression for those exons in cells treated with control siRNAs. f-g, A subset of nine transcripts initially identified as 'hits' (significantly increased abundance (f) or decreased abundance (g)) in the TDP43-knockdown experiment were selected for validation by qRT-PCR. Data are displayed as mean with s.d. of technical replicates from n = 2 independent experiments (unpaired t test, two-sided, P < 0.05).
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NATuRe NeuRoScieNce (Fig. 2d) . Consistent with the TDP-43 depletion experiments, we did not observe significant changes to the abundance of the closely related STMN1 RNA suggesting a specific relationship between TDP-43 and STMN2 ( Fig. 2d and Supplementary Fig. 6e ). Additionally, we did not observe significant differences in TARDBP transcript levels between mutant and control neurons (Fig. 2d) . 
NATuRe NeuRoScieNce TDP-43 regulates STMN2 levels. Due to their broad expression pattern, previous studies have detected links between both PFKP as well as ELAVL3 28, 29 and TDP-43. We, therefore, focused our efforts on exploring how STMN2, which shows a more neuronally restricted expression pattern, might be regulated by TDP-43. STMN2 is one of four proteins belonging to the Stathmin family of microtubule-binding proteins, with functional roles in neuronal cytoskeletal regulation and axonal regeneration pathways 18, 19, 30 . In humans, STMN1 and STMN3 transcripts exhibit ubiquitous expression, whereas STMN2 and STMN4 are enriched in central nervous system tissues 31 . Considering the growing evidence for cytoskeletal defects in ALS [32] [33] [34] and the importance of cytoskeletal function in projection neurons, characterizing a putative relationship between STMN2 and TDP-43 seemed to be of potential relevance to ALS.
To this end, we first examined whether the decline in the STMN2 transcript abundance after TDP-43 knockdown was reflected at the protein level. Following independent RNAi experiments, we performed qRT-PCR with two different sets of primer pairs and found STMN2 (~50-60%) transcript abundance significantly reduced in hMNs relative to controls (Fig. 3a) . Immunoblot assays on protein lysates from these same hMN cultures demonstrated STMN2 protein levels were also significantly reduced following siTDP-43-treatment (Fig. 3b) .
To probe how selective the changes in STMN2 levels were to TDP-43 knockdown, we knocked down two additional ALS-linked genes, FUS and C9ORF72 1, 4 . FUS protein is structurally similar to TDP-43 and is also involved in RNA metabolism. The function of C9ORF72 is under investigation, but a large intronic GGGGCC repeat expansion is responsible for a substantial number ALS and FTD cases through three proposed mechanisms: the creation of long repetitive RNAs, the translation of these repeats into toxic, repetitive dipeptides or haploinsufficiency. Following induction of RNAi targeting TDP-43, FUS or C9ORF72, we found significant downregulation of the respective siRNA-targeted genes by qRT-PCR ( Supplementary Fig. 6a-c) . Although knockdown of TARDBP reduced levels of STMN2, STMN2 levels were unaltered following knockdown of FUS and C9ORF72 (Fig. 3c) . These results confirm that STMN2 downregulation was not a trivial consequence of RNAi induction. Furthermore, these data suggest that reduced function of FUS and C9ORF72 were not sufficient to induce a reduction in STMN2 abundance.
TDP-43 can bind to and regulate several aspects of RNA metabolism. To determine whether TDP-43 associated directly with STMN2 RNA, which contains many TDP-43 binding motifs ( Supplementary Fig. 6f,g ), we developed conditions for TDP-43 immunoprecipitation and subsequent formaldehyde RNA immunoprecipitation (fRIP) (Fig. 3d) . After reversal of cross-linking, we performed qRT-PCR to detect RNA molecules bound to TDP-43. We first examined whether transcripts encoding TDP-43 itself were enriched as this autoregulation is well-established 10 . Indeed, we observed enrichment of TARDBP RNA following TDP-43 pulldown, but not in an IgG control or when we pulled down a distinct ALS-associated protein, SOD-1 (Fig. 3e) . We next asked whether additional transcripts influenced by TDP-43 knockdown, housekeeping transcripts (PGK1, UBC, GAPDH), or a motor neuronspecific transcript (MNX1) were enriched. Of these, we observed strong and significant enrichment for STMN2 transcripts (Fig. 3e) .
TDP-43 suppresses cryptic exon inclusion.
Emerging evidence highlights the importance of nuclear TDP-43 in suppressing nonconserved or cryptic exons to maintain splicing integrity 35 . When cryptic exons are included in RNA transcripts, their inclusion can affect transcript abundance by disrupting translation and promoting nonsense-mediated decay 35 . Interestingly, little or no overlap in the genes regulated by TDP-43 through cryptic exon suppression has been observed between mouse and man 35 . We, therefore, examined our motor neuron sequencing data for evidence of cryptic exons in the 95 human genes reported to contain TDP-43-regulated cryptic exons 36 . We found reads mapping to cryptic exons in nine of these genes including PFKP ( Supplementary Fig. 7a ). Encouraged, we used our data to search for neuronal transcripts that might be regulated by this mechanism. We identified cryptic exons in both ELAVL3 and STMN2 ( Supplementary Fig. 7b,c) . In the case of STMN2, we observed splicing tracks emanating from exon 1 and entering a cryptic exon, but no splice ribbons from the cryptic exon to either exon 2 or other exons downstream (Fig. 3f,g ). Moreover, the inclusion of this cryptic exon would lead to a very early stop codon ( Supplementary Fig. 10h ). As a result, STMN2 transcripts that include this cryptic exon cannot yield functional STMN2 protein.
STMN2 levels tuned by TDP-43 levels and localization. TARDBP mutations and overexpression have been proposed to perturb autoregulation of its transcript leading to altered TDP-43 protein levels 37 . Thus, we asked whether expression of additional wildtype or mutant TDP-43 could act dominantly to influence expression of STMN2. To answer this question in a controlled manner, we knocked-in a single copy of either wildtype TDP-43 or mutant TDP-43 M337V into the AAVS1 safe harbor locus of the HUES3 Hb9::GFP cell line ( Supplementary Fig. 8a ). Genotyping of the AAVS1 locus confirmed single copy integration of each construct ( Supplementary  Fig. 8b ). Following directed differentiation, GFP + hMN purification and RNA isolation, we found that additional expression of either wildtype or mutant TDP-43 significantly depressed the abundance of STMN2 (Supplementary Fig. 8c ). These data together with our siRNA data indicate that both depleting and increasing TDP-43 levels can alter STMN2 expression.
Aggregation and loss of nuclear TDP-43 are pathological hallmarks of ALS. To investigate a potential connection between these postmortem findings and STMN2 abundance, we explored whether MG-132-mediated proteasome inhibition could influence TDP-43 localization in hMNs and serve as a potential model of acute TDP-43 dysfunction. After establishing the range and timing of tolerable proteasome inhibition ( Supplementary Fig. 9a -c), we performed a pulse-chase experiment to determine the consequences of proteasome inhibition on TDP-43 localization ( Supplementary  Fig. 10a ). Strikingly, using the Pearson's coefficient analysis and nuclear to cytoplasmic ratio, we observed that TDP-43 staining in the nucleus was greatly diminished after 24 h (Supplementary Fig. 10b-d) . Following MG-132 washout, we found that TDP-43 staining became indistinguishable from that in unchallenged neurons after 4 days (Supplementary Fig. 10b-d) . Thus, proteasome inhibition in hMNs induced reversible TDP-43 mislocalization.
In ALS patients, TDP-43 mislocalization is associated with accumulation of insoluble TDP-43 protein. After proteasome inhibition in hMNs, we examined TDP-43 levels by immunoblot analysis in both the detergent-soluble and detergent-insoluble fractions. In lysates from neurons treated with MG-132 ( Supplementary Fig. 10a ), we observed a significant decline in soluble TDP-43 ( Supplementary  Fig. 10e ), which could be readily explained by an increase of insoluble TDP-43 found after urea exposure ( Supplementary Fig. 10e ). After establishing that proteasome inhibition induced TDP-43 mislocalization and insolubility, we asked if this change in TDP-43 also influenced STMN2 transcript levels and again found a significant decline in its abundance ( Supplementary Fig. 10f ). We next used RT-PCR with primers spanning into the STMN2 cryptic exon observed after TDP-43 depletion to ask if proteasome inhibition also induced its inclusion in hMNs ( Supplementary Fig. 10g ). Although hMNs growing under normal conditions showed no detectable evidence for this cryptic event, following proteasome inhibition, it could be readily observed ( Supplementary Fig. 10g ) Sequencing of the PCR product confirmed the splice junction and Articles NATuRe NeuRoScieNce premature stop codon within the cryptic splice-form predicted by our RNA-seq analysis ( Supplementary Fig. 10h ). These data connect impaired protein homeostasis to TDP-43 localization and solubility as well as STMN2 levels. We found it notable that an identical cryptic splicing event was induced in STMN2 following either RNAi-mediated TDP-43 depletion or proteasome inhibition induced TDP-43 insolubility.
STMN2 localization in human neurons. Given the importance of TDP-43 in ALS and its tight regulation of STMN2, we wondered Protein levels were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and are expressed relative to the levels in hMNs treated with the siRED control. Similar results were obtained in n = 2 independent experiments. c, qRT-PCR analysis for STMN2 transcript analysis in Hb9::GFP + hMNs treated with siRNAs targeting three ALS-linked genes (TARDBP, FUS and C9ORF72). Data are displayed as mean with s.d. of replicates from n = 2 independent experiments (Dunnett's multiple comparison test, α < 0.05). Similar results were obtained in n = 3 independent experiments. d-e, Formaldehyde RNA immunoprecipitation was used to identify transcripts bound to TDP-43: after TDP-43 immunoprecipitation (d), qRT-PCR analysis was used to test for enrichment of TARDBP transcripts, STMN2, PFKP and ELAVL3 (e) normalized to the sample input then relative to IgG and the housekeeping genes pulled down by TDP-43. Data are displayed as mean with s.d. of replicates for one of n = 2 independent experiments (unpaired t test, two-sided, P < 0.05 compared to the housekeeping genes MNX1, GAPDH and UBC). f-g, Visualization of RNA-seq reads mapping to STMN2 from neurons treated with scrambled siRNAs (f) or siTDP43 (g). Read coverage and splice junctions are shown for alignment of the samples to the human hg19 genome. Splice ribbons from exon 1 to the cryptic exon are highlighted in orange.
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NATuRe NeuRoScieNce if alterations in STMN2 might influence motor axon biology. Supporting previous expression studies 30 , we found that STMN2 protein was selectively expressed in differentiated neurons and could not be as readily detected in stem cells or neuronal progenitors (Supplementary Fig. 6d ). We used immunocytochemistry to probe the subcellular localization of STMN2 and found it both at neurite tips and in peri-nuclear regions of the cell bodies (Fig. 4a) . Further co-staining for the Golgi-associated protein GOLGIN97, indicated STMN2 was localizing to this subcellular compartment (Fig. 4b) . On the basis of rodent studies 18 , STMN2 would be predicted to function at the human growth cone during neurite extension and repair. When we stained hMNs after differentiation and sorting, we observed strong staining of STMN2 at the interface between microtubules and F-actin bundles; cytoskeletal components defining the growth cone (Fig. 4c) .
TDP-43 depletion inhibits neurite and axon growth.
On the basis of predicted STMN2 function, we investigated whether TDP-43 knockdown compromised neurite outgrowth and axonal regeneration in hMNs. Three days after siTDP43 transfection, hMNs were fixed and stained for β -III-tubulin to label neuronal processes. Sholl analysis, which quantifies the number of neurite branches at a given interval from the center of the soma, revealed significantly reduced neurite complexity in neurons treated with siTDP-43 ( Fig. 5a-c) .
To test if reduced TDP-43 levels inhibited axonal regrowth after injury, we plated hMNs in microfluidic devices that permitted axon growth into a chamber distinct from the neuronal cell bodies. Neurons cultured for 7 days in the soma compartment of the device extended axons through the microchannels into the axon chamber. We severed axons without disturbing cell bodies in the soma compartment and then measured axon extension from the microchannel across a time course to assess regrowth after injury. Our analysis revealed significantly reduced regrowth in the siTDP-43-treated neurons for all time points measured ( Fig. 5d-f ).
STMN2 is necessary for normal neurite growth. Because TDP-43 regulates many transcripts, we confirmed that loss of STMN2 was sufficient to induce phenotypes similar those observed after 
Articles
NATuRe NeuRoScieNce TDP-43 knockdown. We used CRISPR/Cas9 to produce a large deletion within STMN2 in two independent hES cell lines (WA01 and HUES3 Hb9::GFP). We confirmed loss of protein expression in differentiated hMNs by both immunoblotting and immunocytochemistry ( Fig. 6a-d) . We then characterized neurite outgrowth in STMN2 −/− mutant hMNs (Fig. 6e) . After 7 days in culture, Sholl analysis revealed significantly reduced neurite extension in STMN2 −/− mutant neurons relative to controls (Fig. 6f,g ). Separately, we cultured neurons in the presence of a ROCK inhibitor, Y-27632, which has been shown to increase neurite extension. The difference in neurite outgrowth was even more striking in these experiments with the molecule enhancing the outgrowth of the STMN +/+ line but not the STMN −/− line (Fig. 6h) . Inactivation of STMN2 in the WA01 background resulted in hMNs with similar outgrowth phenotypes ( Supplementary Fig. 11 ). We also queried whether STMN2 functions in neuronal repair after injury (Fig. 6i) . To this end, hMNs were cultured for 7 days in microfluidic devices before performing axotomy. Our experiments revealed +/+ controls for all time points measured (Fig. 6j,k and Supplementary Fig. 11 ).
STMN2 is altered in postmortem ALS spinal cord. We next asked if our findings were relevant to the motor neurons of ALS patients in vivo. To this end, we used immunohistochemistry to investigate , Wald test and a cutoff of 0.1 for Benjamini-Hochberg adjusted P values with no log 2 fold-change ratio cutoff, g). h-i, Visualization of the cryptic exon for STMN2 from the NINDS datasets for the ventral horns of controls (h) and sporadic ALS patient (i) spinal cords. Read coverage and splice junctions are shown for alignment of the samples to the human hg19 genome. Splice ribbons from exon 1 to the cryptic exon are highlighted in orange.
NATuRe NeuRoScieNce STMN2 expression in control and ALS patient postmortem spinal cord. Similar to our observations in stem cell-derived hMNs, strong STMN2 immunoreactivity was present in the cytoplasmic region of lumbar spinal hMNs, but absent in the surrounding glial cells (Fig. 7a-c) . We determined the percentage of hMNs exhibiting STMN2 immunoreactivity in lumbar spinal cord tissue sections in three controls and in three ALS cases. Consistent with our hypothesis, we found that the percentage of lumbar hMNs with immunoreactivity to STMN2-specific antibody was significantly reduced in sporadic ALS cases (Fig. 7d) . Our results are further supported by several independent expression analyses of ALS postmortem spinal cord samples [38] [39] [40] . We independently interrogated these data and 
NATuRe NeuRoScieNce observed decreased STMN2 transcript levels for the ALS patient samples relative to control samples in each instance (Fig. 7e-g ). For the single study that performed RNA-Seq 40 , we also examined the sequencing reads mapping to STMN2 and identified the presence of the aforementioned cryptic exon in five of the six ALS samples and no control samples (Fig. 7h,i) . These results provide an important in vivo validation of our disease modeling results.
JNK inhibition rescues STMN2 and neurite defects. Finally, we wondered if STMN2 levels might be pharmacologically elevated through post-translational means to rescue TDP-43 depletion induced neuropathy. Previous studies indicated that JNK1 can bind to and phosphorylate STMN2 and that phosphorylation of STMN2 promotes its degradation 41, 42 . We therefore tested whether JNK inhibition could rescue STMN2 levels after TDP-43 knockdown (Fig. 8a) . hMNs were treated with siRNAs then cultured in the presence or absence of SP600125, an established JNK inhibitor. Subsequent immunoblot analysis showed STMN2 protein levels were significantly increased after JNK inhibition (Fig. 8b ) with all uncropped blots available for this and all other experiments in supplementary materials ( Supplementary Fig. 13) . Notably, the reduced levels of STMN2 observed after siTDP43 treatment could be boosted to levels greater than those observed in control hMNs (Fig. 8b) and, importantly, did not affect the levels of TDP-43 (Fig. 8c) .
After rescuing STMN2 protein levels, we investigated whether SP600125 could rescue the TDP-43 depletion induced neuronal phenotypes. Sholl analysis reconfirmed decreased outgrowth following TDP-43 depletion and demonstrated that JNK inhibition significantly rescued outgrowth (Fig. 8d,e) . Last, we determined whether SP600125 could also rescue defects in axonal regrowth after injury (Fig. 8a) . Replicating our previous findings, we observed decreased regeneration following injury in siTDP43-treated neurons (Fig. 8f,g ). SP600125 did not alter axonal repair in neurons treated with scrambled siRNAs (Fig. 8g) . However, JNK inhibition did significantly rescue axon regrowth following TDP-43 depletion (Fig. 8f,g ).
Discussion
An outstanding question has been: what are the mechanistic consequences of TDP-43 mutations and how do their effects relate to the events that occur when TDP-43 becomes pathologically re-localized in patients? Identifying transcripts regulated by TDP-43 provided us the opportunity to explore the potential impact of different types of TDP-43 manipulations relevant to both familial and sporadic disease. First, we addressed whether a subset of the target RNAs identified after TDP-43 depletion change in hMNs produced from patients with TDP-43 mutations. Interestingly, we found modest but significant changes in the expression of a number of interesting genes 43 including the microtubule regulator STMN2. Thus, cells expressing patient mutations displayed partial loss of-function. But if so, how can their dominant nature be explained?
Upon overexpression, TDP-43 is prone to aggregation 7 , and some studies suggest mutant TDP-43 is prone to aggregation when expressed at native levels in patient-specific motor neurons 24, 26, 27 . To determine whether aggregation or loss of nuclear mutant TDP-43 could be contributing to decreased expression, we carefully monitored TDP-43 in these patient hMNs, but could not detect such a defect. We are, however, confident that if larger scale aggregation, or nuclear loss of mutant TDP-43 were occurring in iPSC hMNs that we would have detected it, as we found that proteasome inhibition induced dramatic nuclear loss of TDP-43 along with its insoluble accumulation. These results are akin to our previous results with mutant SOD-1 being selectively insoluble after proteasome inhibition 44 . We also found these data captivating because disrupted proteostasis induced by any number of ALS implicated mutations or events could be upstream of the most common histopathological finding in sALS, TDP-43 pathology and our finding that TDP-43 targets are depleted following proteasome inhibition is consistent with that model. This model is attractive because it reconciles how overexpression of an additional transgenic copy of TDP-43 might lead to a decrease in STMN2 expression. Two recent publications describing mice with endogenous TDP-43 mutations also provide insight into the potential gain and loss of TDP-43 functions. Both studies suggest splicing abnormalities are a major consequence of TDP-43 mutations 37, 45 . Our study also spotlights splicing defects downstream of TDP-43 perturbations, and, because of the lack of cryptic exon conservation among species 35 , showcases the advantage of human cellular disease models in identifying STMN2 RNA as a TDP-43 target.
Interestingly, partial depletion of FUS and C9ORF72 did not alter STMN2 abundance. It is well known that patients with C9ORF72 display TDP-43 pathology and consistent with this we found reduced STMN2 levels in postmortem material from such patients. These findings suggest that either the gain of function effects of the C9ORF72 mutation or further events subsequent to knockdown are required to induce TDP-43 pathology and reduced STMN2 levels. In the instance of patients with mutations in FUS who do not display TDP-43 pathology, it seems plausible that distinct defects in RNA metabolism underlie neuropathy. While they are beyond the scope of this study, further studies with iPSC-derived neurons from FUS and C9ORF72 patients could shed light on these hypotheses.
The Stathmin family of proteins are regulators of microtubule stability 30 . Using gene editing we demonstrated STMN2 has important functions in both motor axon outgrowth and regeneration, phenocopying results in neurons with diminished TDP-43 levels. Although hMNs generated in vitro share many molecular and functional properties with bona fide motor neurons 13 , the in vivo validation of stem cell-based ALS model discoveries is a critical test of their relevance 46 . Using spinal cord tissues and published expression studies, we provide in vivo evidence corroborating the finding that STMN2 levels are altered in ALS. Furthermore, we found that the probable mechanism for this decline, as in our cell models, was through splicing into a cryptic exon. Finally, we demonstrate JNK inhibition increases STMN2 levels, which was sufficient to rescue axonal phenotypes induced by TDP-43 depletion. While we suggest that restoring STMN2 levels in ALS patients to normal levels is an attractive target, it is important this be done with care as overexpression of Stathmins can cause Golgi fragmentation as shown in the transgenic SOD1 mouse model of ALS 47 .
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Methods
Cell culture and differentiation of hESCs and human induced pluripotent stem cells into motor neurons. Pluripotent stem cells were grown with mTeSR1 medium (Stem Cell Technologies) on tissue culture dishes coated with Matrigel (BD Biosciences), and maintained in 5% CO 2 incubators at 37 °C. Stem cells were passaged as small aggregates of cells after 1 mM EDTA treatment. 10 μ M ROCK inhibitor (Sigma, Y-27632) was added to the cultures for 16-24 h after dissociation to prevent cell death. The HUES3 Hb9::GFP cell line has been previously described 12, 48 . Motor neuron differentiation was achieved using a modified 14-day strategy. This approach relies on neural induction through small molecule inhibition of SMAD signaling, accelerated neural differentiation through FGF and NOTCH signaling inhibition and motor neuron patterning through the activation of retinoic acid and Sonic Hedgehog signaling pathways. In brief, embryonic stem cells were dissociated to single cells using accutase (Stem Cell Technologies) and plated at a density of 80,000 cells per cm 2 Cell acquisition and authentication. The hESCs and iPSCs used in this study were previously approved by the institutional review boards of Harvard University, Massachusetts General Hospital and Columbia University. Specific point mutations were confirmed by PCR amplification followed by Sanger sequencing. Weekly, our lab checks for mycoplasma contamination using the MycoAlert kit (Lonza) with no cell lines used in this study testing positive. The use of these cells at Harvard was further approved and determined not to constitute Human Subjects Research by the Committee on the Use of Human Subjects in Research at Harvard University.
FACS of hMNs. After 14 days, differentiated cultures were dissociated to single cells using accutase treatment for 1 h inside a 5% CO 2 per 37 °C incubator. Repeated (10-20 times) but gentle pipetting with a 1,000 μ l Pipetman was used to achieve a single cell preparation. Cells were spun down, washed × 1 with PBS and resuspended in sorting buffer (× 1 cation-free PBS 15 mM HEPES at pH 7 (Gibco), 1% BSA (Gibco), × 1 penicillin-streptomycin (Gibco), 1 mM EDTA and DAPI (1 µ g ml
−1
). Cells were passed through a 45 μ m filter immediately before FACS analysis and purification. The BD FACS Aria II cell sorter was routinely used to purify Hb9::GFP + cells into collection tubes containing motor neuron medium (Neurobasal (Life Technologies), × 1 N-2 supplement (Gibco), B-27 supplement (Gibco), GlutaMax and NEAA) with 10 μ M ROCK inhibitor (Sigma, Y-27632) and 10 ng ml −1 of neurotrophic factors; glial cell-derived neurotrophic factor (GDNF), brain-derived neurotrophic factor (BDNF) and ciliary neurotrophic factor (CNTF) (R&D). Forward and side scatter was used to resolve cells from debris with doublet discrimination by forward scatter area versus forward scatter width. DAPI signal was then used to determine cell viability and differentiated cells not exposed to motor neuron patterning molecules (retinoic acid and sag) were used as negative controls to gate for green fluorescence.
For cell lines not containing the Hb9::GFP reporter, the BD Lyoplate was used to identify a cell surface signature 49 . After 14 days of differentiation, HUES3 Hb9::GFP cultures were dissociated to single cells using Accutase supplemented with DNAse I, washed by gentle pipetting and 500,000 cells were aliquoted across three 96-well plates and stained for 242 monoclonal antibodies (BD Lyoplate, BD Bioscience 560747). Cells were washed, stained with secondary antibody conjugated to Alexa Fluor 647, washed, fixed and analyzed using the high throughput sampler module of BD LSR II. To sort cells on the basis of BD Lyoplate findings, single cell suspensions were incubated with antibodies against NCAM (BD Bioscience, BDB557919, 1/200) and EpCAM (BD Bioscience, BDB347198, 1/50) for 25 min in sorting buffer, then washed once with PBS × 1 and resuspended in sorting buffer. The population that was negative for EpCAM but positive for NCAM was sorted. For RNA-Seq experiments, 200,000 GFP + cells per well were plated in 24-well tissue culture dishes pre-coated with Matrigel. Motor neuron medium supplemented with 10 ng ml −1 of each GDNF, BDNF and CNTF (R&D Systems) was used to feed and mature the purified hMNs. RNA-Seq experiments and most downstream assays were carried with d10 purified hMNs (10 days in culture after FACS) grown plates coated with 0,1 mg ml −1 poly-D-lysine (Invitrogen) and 5 μ g ml −1 laminin (Sigma-Aldrich) at a concentration of around 130,000 cells per cm 2 .
RNAi. RNAi in cultures of purified GFP
+ motor neurons was induced with Silencer Select siRNAs (Life Technologies) targeting the TDP-43 mRNA or with a non-targeting siRNA control with scrambled sequence that is not predicted to bind to any human transcripts. Lyophilized siRNAs were resuspended in nuclease-free water and stored at − 20 o C as 20 μ M stocks until ready to use. For transfection, siRNAs were diluted in Optimem (Gibco) and mixed with RNAimax (Invitrogen) according to manufacturer's instructions. After 30 min incubation, the mix was added drop-wise to the motor neuron cultures, so that the final siRNA concentration in each well was 60 nM in 1/1 Optimem/motor neuron medium (Neurobasal (Life Technologies, N2 supplement (Gibco), B-27 supplement (Gibco), GlutaMax and NEAA) and 10 ng ml −1 of each GDNF, BDNF and CNTF (R&D). 12-16 h post-transfection media was changed. RNA-Seq experiments and validation assays were carried out with material collected 4 days after transfection.
Immunocytochemistry. For immunofluorescence, cells were fixed with ice-cold 4% PFA for 15 min at 4 °C, permeabilized with 0.2% Triton-X in × 1 PBS for 45 min and blocked with 10% donkey serum in × 1 PBS-T (0.1% Tween-20) for 1 h. Cells were then incubated overnight at 4 °C with primary antibody (diluted in blocking solution). At least four washes (5 min incubation each) with × 1 PBS-T were carried out, before incubating the cells with secondary antibodies for 1 h at room temperature (diluted in blocking solution). Nuclei were stained with DAPI. The following antibodies were used in this study: Hb9 (1/100, DSHB, MNR2 81.5C10-c), TUJ1 (1/1,000, R&D Systems MAB NL493), MAP2 (1/10,000, Abcam ab5392), GFP (1/500, Life Technologies, A10262), Islet1 (1/500, Abcam ab20670), TDP-43 (1/500, ProteinTech Group) and STMN2 (1/4,000, Novus). Secondary antibodies used (488, 555, 594 and 647) were AlexaFluor (1/1,000, Life Technologies). Images were acquired using a Nikon Eclipse Ti microscope and analyzed using NISElements (Nikon).
Immunoblot assays. For analysis of TDP-43 and STMN2 protein expression levels, d10 motor neurons were lysed in RIPA buffer (150 mM sodium chloride; 1% Triton-X-100; 0.5% sodium deoxycholate; 0.1% SDS; 50 mM Tris pH 8.0) containing protease and phosphatase inhibitors (Roche) for 20 min on ice and centrifuged at high speed. 200 μ l of RIPA buffer per well of 24-well culture were routinely used, which yielded ~20 μ g of total protein as determined by BCA (Thermo Scientific). After two washes with RIPA buffer, insoluble pellets were resuspended in 200 μ l of urea buffer (Bio-Rad). For immunoblot assays 2-3 μ g of total protein were separated by SDS-PAGE (Bio-Rad), transferred to polyvinylidene difluoride membranes (Bio-Rad) and probed with antibodies against TDP-43 (1/1,000, ProteinTech Group), GAPDH (1/1,000, Millipore) and STMN2 (1/3,000, Novus). Insoluble pellets were loaded on the basis of protein concentration of correspondent RIPA-soluble counterparts. The same polyvinylidene difluoride membrane was immunoassayed 2-3 times using Restore PLUS Western Blot Stripping Buffer (Thermo Scientific). GAPDH levels were used to normalized each sample, and LiCor software (Image Studios) was used to quantitate protein band signal. Full size blots have been provided (Supplementary Fig. 13) RNA preparation, qRT-PCR and RNA-sequencing. Total RNA was isolated from d10 motor neurons for RNA-Seq experiments and validation assays using Trizol LS (Invitrogen) according to manufacturer's instructions. 500 μ l were added per well of the 24-well cultures. A total of 300-1,000 ng of total RNA was used to synthesize cDNA by reverse transcription according to the iscript kit (Bio-Rad). qRT-PCR was then performed using SYBR green (Bio-Rad) and the iCycler system (Bio-Rad). Quantitative levels for all genes assayed were normalized using GAPDH expression. Normalized expression was displayed relative to the relevant control sample. For comparison between patient lines, normalized expression was displayed relative to the average of pooled data points. The qPCR experiment comparing control and ALS cell lines was performed with five control lines and four patient lines with three technical replicates. All primer sequences are available on request. For next-generation RNA-Seq, two independent experiments were performed (Exp. 1 and Exp. 2) with multiple unique siRNAs used for the two groups control (siRED, siSCR1 and siSCR2) versus siTDP43 (siTDP1 and siTDP2) with a total of n = 15 samples. After RNA extraction, samples with RNA integrity numbers above 7.5, determined by a BioAnalyzer, were used for library preparation. In brief, RNA sequencing libraries were generated from ~250 ng of total RNA using the illumina TruSeq RNA kit V.2, according to the manufacturer's directions. Libraries were sequenced at the Harvard Bauer Core Sequencing facility on a HiSeq 2000 platform. All FASTQ files were analyzed using the bcbioRNASeq workflow and toolchain 50 . The FASTQ files were aligned to the GRCh37/hg19 reference genome. Differential expression testing was performed using DESeq2 suite of bioinformatics tools 51 . The DEXSeq module of Bioconductor was used to identify differential splicing 52 . We used salmon to generate the counts and tximport to load them at gene level 53, 54 . All P values are then corrected for multiple comparisons using the method of Benjamini and Hochberg 55 . We used an adjusted P value cutoff of 0.05 with no log fold-change ratio cutoff for differential gene expression analysis and a 0.1 cutoff with no log fold-change ratio cutoff for differential exon usage.
TDP-43 localization analysis.
For analysis of TDP-43 nuclear localization analysis, hMNs were stained for TDP-43 (ProteinTech), β -III tubulin (R&D Systems) and counterstained with DAPI. Images were acquired using a Nikon Eclipse Ti microscope. β -III tubulin staining was used to determine the cell body as the Articles NATuRe NeuRoScieNce region of interest and then the Pearson's correlation coefficient was calculated for TDP-43 and DAPI staining using NIS-Elements (Nikon) with a minimum of 30 neurons analyzed. NIS-Elements was used to segment cells into the nuclear (DAPI positive) and cytoplasmic (β -III tubulin positive DAPI negative) regions. The mean TDP-43 intensity in these two regions were used to calculate the nuclear to cytoplasmic ratio for TDP-43 immunofluorescence.
Electrophysiology recordings. GFP
+ motor neurons were plated at a density of 5,000 cells per cm 2 on poly-D-lysine/laminin-coated coverslips and cultured for 10 days in MN medium, conditioned for 2-3 days by mouse glial cells and supplemented with 10 ng ml −1 of each GDNF, BDNF and CNTF (R&D Systems). Electrophysiology recordings were carried out as previously reported 44, 56 . Briefly, whole-cell voltage-clamp or current-clamp recordings were made using a Multiclamp 700B (Molecular Devices) at room temperature (21-23 °C) . Data were digitized with a Digidata 1440A A/D interface and recorded using pCLAMP 10 software (Molecular Devices). Data were sampled at 20 kHz and low-pass filtered at 2 kHz. Patch pipettes were pulled from borosilicate glass capillaries on a Sutter Instruments P-97 puller and had resistances of 2-4 MW. The pipette capacitance was reduced by wrapping the shank with Parafilm and compensated for using the amplifier circuitry. Series resistance was typically 5-10 MW, always less than 15 MW, and compensated by at least 80%. Linear leakage currents were digitally subtracted using a P/4 protocol. Voltages were elicited from a holding potential of − 80 mV to test potentials ranging from − 80 to 30 mV in 10 mV increments. The intracellular solution was a potassium-based solution and contained KCl, 150; MgCl 2 , 2; HEPES, 10; Mg ATP, 4; EGTA, 1 (pH 7.4 with KOH). The extracellular was sodium-based and contained NaCl, 135; KCl, 5; CaCl 2 , 2; MgCl 2 , 1; glucose, 10; HEPES, 10, pH 7.4 with NaOH). Kainate was purchased from Sigma. For multielectrode array analysis, hMNs were plated onto the multielectrode array plate and co-cultured with mouse p0-2 astrocytes (Axion Biosystems M768-KAP-96). The neuronal activities including spike and bursting number for individual wells were measured and analyzed by Axion NeuroMetric Tool software. STMN2 knockout generation. STMN2 guide RNAs were designed using the following web resources: CHOPCHOP (https://chopchop.rc.fas.harvard.edu) from the Schier Laboratory 57 . Guides were cloned into a vector containing the human U6 promotor (custom synthesis, Broad Institute) followed by the cloning site available by cleavage with BbsI, as well as ampicillin resistance. To perform the cloning, all the gRNAs were modified before ordering. The following modifications were used ito generate overhangs compatible with a BbsI sticky end: if the 5′ nucleotide of the sense strand was not a G, this nucleotide was removed and substituted with a G; for the reverse complement strand, the most 3′ nucleotide was removed and substituted with a C, while AAAC was added to the 5′ end. The resulting modified STMN2 gRNA sequences were used for Cas9 nuclease genome editing: guide 1: 5′ CACCGTATAGATGTTGATGTTGCG 3′ (Exon 2), guide 2: 5′ CACCTGAAACAATTGGCAGAGAAG 3′ (Exon 3), guide 3: 5′ CACCAGTCCTTCAGAAGGCTTTGG 3′ (Exon 4). Cloning was performed by first annealing and phosphorylating both the gRNAs in PCR tubes. 1 µ l of both the strands at a concentration of 100 µ M was added to 1 µ l of T4 PNK (New England Biolabs), 1 µ l of T4 ligation buffer and 6 µ l of H 2 O. The tubes were placed in the thermocycler and incubated at 37 °C for 30 min, followed by 5 min at 95 °C and a slow ramp down to 25 °C at a rate of 5 °C per min. The annealed oligos were subsequently diluted 1/100 and 2 µ l was added to the ligation reaction containing 2 µ l of the 100 µ M pUC6 vector, 2 µ l of NEB buffer 2.1, 1 µ l of 10 mM DTT, 1 µ l of 10 mM ATP, 1 µ l of BbsI (New England Biolabs), 0.5 µ l of T7 ligase (New England Biolabs) and 10.5 µ l of H 2 O. This solution was incubated in a thermocycler with the following cycle, 37 °C for 5 min followed by 21 °C for 5 min, repeated a total of six times. The vectors were subsequently cloned in OneShot Top10 (ThermoFisher Scientific) cells and plated on LB-ampicilin agar plates and incubated overnight on 37 °C. The vectors were isolated using the Qiagen MIDI-prep kit (Qiagen) and measured DNA concentration using the nanodrop. Proper cloning was verified by sequencing the vectors by Genewiz using the M13F(− 21) primer.
Stem cell transfection was performed using the Neon Transfection System (ThermoFisher Scientific) with the 100 µ l kit (ThermoFisher Scientific). Prior to the transfection, stem cells were incubated in mTeSR1 containing 10 µ M ROCK inhibitor for 1 h. Cells were subsequently dissociated by adding accutase and incubating for 5 min at 37 °C. Cells were counted using the Countess and resuspended in R medium at a concentration of 2.5 × 10 6 cells per ml. The cell solution was then added to a tube containing 1 µ g of each vector containing the guide and 1.5 µ g of the pSpCas9n(BB)− 2A-Puro (PX462) V2.0, a gift from Feng Zhang (Addgene). The electroporated cells were immediately released in preincubated 37 °C mTeSR medium containing 10 µ M of ROCK inhibitor in a 10 cm dish when transfected with the puromycin resistant vector.
Twenty-four hours after transfection with the Puromycin resistant vector, selection was started. Medium was aspirated and replaced with mTESR1 medium containing different concentrations of Puromycin: 1 µ g µ l . After an additional 24 h, the medium was aspirated and replaced with mTeSR1 medium. Cells were cultured for 10 days before colony picking the cells into a 24-well plate for expansion.
Genomic DNA was extracted from puromycin-selected colonies using the Qiagen DNeasy Blood and Tissue kit (Qiagen) and PCR screened to confirm the presence of the intended deletion in the STMN2 gene. PCR products were analyzed after electrophoresis on a 1% Agarose Gel. In brief, the targeted sequence was PCR amplified by a pair of primers external to the deletion, designed to produce a 1,100 base pair deletion-band to detect deleted clones. Sequences of the primers used are as follows: OUT_FWD, 5′ GCAAAGGAGTCTACCTGGCA 3′ and OUT_REV, 5′ GGAAGGGTGACTGACTGCTC 3′ . Knockout lines were further confirmed using immunoblot analysis.
Neurite outgrowth assay. Individual Tuj1-positive neurons used for Sholl analyses 58 were randomly selected and imaged using a Nikon Eclipse TE300 with a × 40 objective. The neurites were traced using the ImageJ (NIH) plugin NeuronJ 58 , and Sholl analysis was carried out using the Sholl tool of Fiji 59 , quantifying the number of intersections at 10-μ m intervals from the cell body. The Sholl analysis was carried out on a minimum of n = 50 neurons. Statistical analysis was carried out by comparing the number of intersections of knockout clones with the parental wildtype line for each 10-μ m interval using Prism 7 (Graph Pad). Significance was assessed by a standard Student's t-test, with a P value of P < 0.05 considered as significant.
Axotomy. Sorted motor neurons were cultured in standard neuron microfluidic devices 60 (SND150, XONA Microfluidics) mounted on glass coverslips coated with with 0.1 mg ml −1 poly-L-ornithine (Sigma-Aldrich) diluted in 50 mM Borate buffer, pH = 8.5 and 5 μ g ml −1 laminin (Invitrogen) at a concentration of around 250,000 neurons per device. Axotomy was performed at day 7 of culture by repeated vacuum aspiration and reperfusion with × 1 PBS in the axon chamber until axons were cut effectively without disturbing cell bodies in the soma compartment. For HUES3 experiments, two independent replicates were performed with the first using one device and 20-30 neurites measured, and for the second experiment three devices were used with 70-90 neurites measured. For the WA01 cell lines, one replicate was performed with two devices and 50-60 neurites measured.
TDP-43 and STMN2 immunohistochemical analyses. Postmortem samples from three sporadic ALS cases (1 male, 2 female) and three controls (2 male, 1 female) (no evidence of spinal cord disease) were gathered from the Massachusetts Alzheimer's Disease Research Center in accordance with Partners and Harvard International Review Board protocols. Histologic analysis of TDP-43 immunoreactivity (rabbit polyclonal, ProteinTech Group) was performed to confirm the diagnosis. For STMN2 analyses, sections of formalin fixed lumbar spinal cord were stained using standard immunohistochemical procedure with the exception that citrate buffer antigen retrieval was performed before blocking. Briefly, samples were rehydrated, rinsed with water, blocked in 3% hydrogen peroxide then normal serum, incubated with primary STMN2 rabbit-derived antibody (1/100 dilution, Novus), followed by incubation with the appropriate secondary antibody (anti-rabbit IgG conjugated to horseradish peroxidase 1/200), and exposure to ABC Vectastain kit and DAB peroxidase substrate, and briefly counterstained with hematoxylin before mounting. Multiple levels were examined for each sample.
STMN2 splicing analysis. Total RNA was isolated from neurons using RNeasy Mini Kit (Qiagen) according to manufacturer's instructions. A total of 300-1,000 ng of total RNA was used to synthesize complimentary DNA by reverse transcription according to the iscript kit (Bio-Rad). RT-PCR was then performed using one cryptic exon-specific primer and then analyzed using the Agilent 2200 Tapestation.
Data presentation and statistical analysis. In the figure elements, bars and lines represent the median with error bars representing standard deviation. The box and whisker plots display the minimum to maximum. Data distribution was assumed to be normal but this was not formally tested. Unless stated otherwise, the statistical analyses were performed using a two-tail unpaired Student's t-test, with a P value of *P < 0.05 considered as significant using Prism 7 (Graph Pad).
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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Sample size
No statistical methods were used to pre-determine sample sizes but our sample sizes are similar to those reported in previous publications Data exclusions No data were excluded from the analyses.
Replication
For the RNAi experiments, replication was achieved through multiple independent differentiations and through using two unique siRNAs for the control and siTDP-43 groups. For the iPS cell studies, we used multiple control cell lines and all available mutant TDP-43 lines for replication. For the STMN2 knockout studies, we generated knockout in two distinct hES cell lines for replication. Technical replication was used throughout for molecular studies. All attempts at replication were successful.
Randomization No randomization was used. We compared specifically designated control samples and test samples through either treatment or genetic information.
Blinding
Blinding was used for the Sholl analysis for the researcher tracing the neurites. For other experiments, data collection and analysis were not performed blind to the conditions of the experiments.
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